eISSN: 1897-4252
ISSN: 1731-5530
Kardiochirurgia i Torakochirurgia Polska/Polish Journal of Thoracic and Cardiovascular Surgery
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2019
vol. 16
 
Share:
Share:
abstract:
Original paper

The usefulness of left ventricular endomyocardial biopsy in clinical decision making in patients with unexplained heart failure

Adam Krajewski
1
,
Przemysław Trzeciak
1
,
Grzegorz Słonka
1
,
Alicja Nowowiejska-Wiewióra
1
,
Jacek Piegza
1
,
Krzysztof Dyrbuś
1
,
Mariusz Gąsior
1

  1. 3rd Chair and Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland
Kardiochir Torakochir Pol 2019; 16 (4): 173-179
Online publish date: 2020/01/15
View full text Get citation
 
PlumX metrics:
Introduction
In recent years, the recommendations for an endomyocardial biopsy (EMB) were significantly extended. However, the proposed criteria are based on the consensus of experts and require further clinical trials.

Aim
To present the results of our diagnostic and therapeutic management based on left ventricular EMB (LV-EMB) in patients with unexplained heart failure (HF).

Material and methods
LV-EMBs were performed between August 2016 and March 2019. Bioptates analysis included histological, immunohistochemical and viral genome examinations. Patients meeting the inclusion criteria had additional immunosuppressive treatment.

Results
LV-EMBs were performed in 30 patients. The mean ± SD age was 38.9 ±7.6 years. About 75% of patients were in NYHA class III or IV, eight were in cardiogenic shock, and four required intra-aortic balloon pump support. Fourteen patients had myocarditis and four had a viral infection. In 9 patients, steroid therapy was implemented. During the mean ± SD observational period of 10.5 ±8.1 months, all patients survived, and 11 had an ejection fraction (EF) of over 35%, of whom 6 (66%) were on additional immunosuppressive therapy and 5 (24%) on standard HF therapy (HR = 2.85; 95% CI: 0.86–9.36; p = 0.08). An increase of > 20 percentage points in the absolute EF was observed in 4 (44%) patients on steroid therapy and 3 (14%) on standard HF therapy (HR = 2.32; 95% CI: 0.51–10.39; p = 0.27).

Conclusions
An LV-EMB performed by skilled physicians is a safe procedure, verifies the cardiac magnetic resonance results, and allows the use of additional therapeutic options in patients with unexplained HF.

keywords:

left ventricular biopsy, myocarditis, heart failure

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.